Cargando…
Clinical spectrum of high-titre GAD65 antibodies
OBJECTIVE: To determine clinical manifestations, immunotherapy responsiveness and outcomes of glutamic acid decarboxylase-65 (GAD65) neurological autoimmunity. METHODS: We identified 323 Mayo Clinic patients with high-titre (>20 nmol/L in serum) GAD65 antibodies out of 380 514 submitted anti-GAD6...
Autores principales: | Budhram, Adrian, Sechi, Elia, Flanagan, Eoin P, Dubey, Divyanshu, Zekeridou, Anastasia, Shah, Shailee S, Gadoth, Avi, Naddaf, Elie, McKeon, Andrew, Pittock, Sean J, Zalewski, Nicholas L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142435/ https://www.ncbi.nlm.nih.gov/pubmed/33563803 http://dx.doi.org/10.1136/jnnp-2020-325275 |
Ejemplares similares
-
LGI1 antibody encephalitis: acute treatment comparisons and outcome
por: Rodriguez, Andrew, et al.
Publicado: (2022) -
Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management
por: Abboud, Hesham, et al.
Publicado: (2021) -
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management
por: Abboud, Hesham, et al.
Publicado: (2021) -
Elevated LGI1‐IgG CSF index predicts worse neurological outcome
por: Gadoth, Avi, et al.
Publicado: (2018) -
LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
por: Binks, Sophie N M, et al.
Publicado: (2018)